Another one, acetylsalicylic acid, an NF-κB inhibitor, is now in a phase II clinical trial for severe influenza, based on its antiviral and additional anti-inflammatory effects (Mazur et al., 2007). This evidence concerns the gene NFKB1 and influenza.